![]() | |
Clinical data | |
---|---|
Trade names | Nurtec ODT, Vydura |
Other names | BHV-3000, BMS-927711 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a620031 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Calcitonin gene-related peptide receptor antagonist |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H28F2N6O3 |
Molar mass | 534.568 g·mol−1 |
3D model ( JSmol) | |
| |
|
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. [7] [9] It is taken by mouth to dissolve on or under the tongue. [7] It works by blocking CGRP receptors. [10]
In the United States, rimegepant was approved for treating acute migraine in February 2020, [11] and its approval was extended to preventing episodic migraine in June 2021. [7] It is produced and marketed by Pfizer. [12] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel. [13] [14] [15] It was approved for medical use in Canada in December 2023. [4]
Rimegepant is indicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults. [7] [9] [8]
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. [10]
Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020. [11] [16] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches. [9]
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine. [17] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC. [17] Rimegepant was approved for medical use in the European Union in April 2022. [8] [18]
{{
cite web}}
: CS1 maint: archived copy as title (
link)
![]() | |
Clinical data | |
---|---|
Trade names | Nurtec ODT, Vydura |
Other names | BHV-3000, BMS-927711 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a620031 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Calcitonin gene-related peptide receptor antagonist |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H28F2N6O3 |
Molar mass | 534.568 g·mol−1 |
3D model ( JSmol) | |
| |
|
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. [7] [9] It is taken by mouth to dissolve on or under the tongue. [7] It works by blocking CGRP receptors. [10]
In the United States, rimegepant was approved for treating acute migraine in February 2020, [11] and its approval was extended to preventing episodic migraine in June 2021. [7] It is produced and marketed by Pfizer. [12] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel. [13] [14] [15] It was approved for medical use in Canada in December 2023. [4]
Rimegepant is indicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults. [7] [9] [8]
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. [10]
Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020. [11] [16] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches. [9]
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine. [17] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC. [17] Rimegepant was approved for medical use in the European Union in April 2022. [8] [18]
{{
cite web}}
: CS1 maint: archived copy as title (
link)